Skip to main content
Top
Published in: Rheumatology International 1/2014

01-01-2014 | Original Article

Anti-arthritic effects of FasL gene transferred intra-articularly by an inducible lentiviral vector containing improved tet-on system

Authors: Qingyu Shi, Xuebi Tian, Yinlin Zhao, Huiyu Luo, Yuke Tian, Ailin Luo

Published in: Rheumatology International | Issue 1/2014

Login to get access

Abstract

The objective of this study is to construct and identify an inducible lentiviral vector containing improved tet-on system and FasL gene and observe its effects on pristane-induced arthritis (PIA). FasL gene was amplified from the spleen of Lewis rats by RT-PCR. The tet-on system was improved with insertion of a chicken chromatin insulator (cHS4) element and an rtTA-dependent, tet-responsive element containing modifications of the tetO sequence (TRE-tight1). Pro-apoptosis effect of the vector pTREFasLcHS4V16 on synovial cells was evaluated by flow cytometer in vitro. Anti-arthritis effects of the vector on PIA after intra-articular injection were observed by clinical evaluation and joint histology. Cytokines in synovial tissue were measured by ELISA. The recombinant inducible lentiviral vector pTREFasLcHS4V16 was successfully constructed. The expression response and the pro-apoptosis effects of the vector were doxycycline dose-dependent. The vector injected intra-articularly attenuated the severity of PIA and decreased the level of cytokines in inflamed joints. pTREFasLcHS4V16 with an improved tet-on system can precisely regulate the expression of FasL gene and apoptosis. Anti-arthritis effects were observed after intra-articular injection of the inducible vector.
Literature
1.
go back to reference Liu H, Pope RM (2004) Apoptosis in rheumatoid arthritis: friend or foe. Rheum Dis Clin North Am 30:603–625PubMedCrossRef Liu H, Pope RM (2004) Apoptosis in rheumatoid arthritis: friend or foe. Rheum Dis Clin North Am 30:603–625PubMedCrossRef
2.
go back to reference Pope RM (2002) Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat Rev Immunol 2:527–535PubMedCrossRef Pope RM (2002) Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat Rev Immunol 2:527–535PubMedCrossRef
3.
go back to reference Peng SL (2006) Fas (CD95)-related apoptosis and rheumatoid arthritis. Rheumatology (Oxford) 45:26–30CrossRef Peng SL (2006) Fas (CD95)-related apoptosis and rheumatoid arthritis. Rheumatology (Oxford) 45:26–30CrossRef
4.
go back to reference Asahara H, Hasumuna T, Kobata T, Yagita H, Okumura K, Inoue H, Gay S, Sumida T, Nishioka K (1996) Expression of Fas antigen and Fas ligand in the rheumatoid synovial tissue. Clin Immunol Immunopathol 81:27–34PubMedCrossRef Asahara H, Hasumuna T, Kobata T, Yagita H, Okumura K, Inoue H, Gay S, Sumida T, Nishioka K (1996) Expression of Fas antigen and Fas ligand in the rheumatoid synovial tissue. Clin Immunol Immunopathol 81:27–34PubMedCrossRef
5.
go back to reference Pundt N, Peters MA, Wunrau C, Strietholt S, Fehrmann C, Neugebauer K, Seyfert C, van Valen F, Pap T, Meinecke I (2009) Susceptibility of rheumatoid arthritis synovial fibroblasts to FasL- and TRAIL-induced apoptosis is cell cycle-dependent. Arthritis Res Ther 11:R16PubMedCentralPubMedCrossRef Pundt N, Peters MA, Wunrau C, Strietholt S, Fehrmann C, Neugebauer K, Seyfert C, van Valen F, Pap T, Meinecke I (2009) Susceptibility of rheumatoid arthritis synovial fibroblasts to FasL- and TRAIL-induced apoptosis is cell cycle-dependent. Arthritis Res Ther 11:R16PubMedCentralPubMedCrossRef
6.
go back to reference Zhang H, Gao G, Clayburne G, Schumacher HR (2005) Elimination of rheumatoid synovium in situ using a Fas ligand ‘gene scalpel’. Arthritis Res Ther 7:R1235–R1243PubMedCentralPubMedCrossRef Zhang H, Gao G, Clayburne G, Schumacher HR (2005) Elimination of rheumatoid synovium in situ using a Fas ligand ‘gene scalpel’. Arthritis Res Ther 7:R1235–R1243PubMedCentralPubMedCrossRef
7.
go back to reference Okamoto K, Asahara H, Kobayashi T, Matsuno H, Hasunuma T, Kobata T, Sumida T, Nishioka K (1998) Induction of apoptosis in the rheumatoid synovium by Fas ligand gene transfer. Gene Ther 5:331–338PubMedCrossRef Okamoto K, Asahara H, Kobayashi T, Matsuno H, Hasunuma T, Kobata T, Sumida T, Nishioka K (1998) Induction of apoptosis in the rheumatoid synovium by Fas ligand gene transfer. Gene Ther 5:331–338PubMedCrossRef
8.
go back to reference Adriaansen J, Vervoordeldonk MJ, Tak PP (2006) Gene therapy as a therapeutic approach for the treatment of rheumatoid arthritis: innovative vectors and therapeutic genes. Rheumatology (Oxford) 45:656–668CrossRef Adriaansen J, Vervoordeldonk MJ, Tak PP (2006) Gene therapy as a therapeutic approach for the treatment of rheumatoid arthritis: innovative vectors and therapeutic genes. Rheumatology (Oxford) 45:656–668CrossRef
9.
go back to reference Weber W, Fussenegger M (2006) Pharmacologic transgene control systems for gene therapy. J Gene Med 8:535–556PubMedCrossRef Weber W, Fussenegger M (2006) Pharmacologic transgene control systems for gene therapy. J Gene Med 8:535–556PubMedCrossRef
10.
go back to reference Osti D, Marras E, Ceriani I, Grassini G, Rubino T, Vigano D, Parolaro D, Perletti G (2006) Comparative analysis of molecular strategies attenuating positional effects in lentiviral vectors carrying multiple genes. J Virol Methods 136:93–101PubMedCrossRef Osti D, Marras E, Ceriani I, Grassini G, Rubino T, Vigano D, Parolaro D, Perletti G (2006) Comparative analysis of molecular strategies attenuating positional effects in lentiviral vectors carrying multiple genes. J Virol Methods 136:93–101PubMedCrossRef
11.
go back to reference Apparailly F, Millet V, Noel D, Jacquet C, Sany J, Jorgensen C (2002) Tetracycline-inducible interleukin-10 gene transfer mediated by an adeno-associated virus: application to experimental arthritis. Hum Gene Ther 13:1179–1188PubMedCrossRef Apparailly F, Millet V, Noel D, Jacquet C, Sany J, Jorgensen C (2002) Tetracycline-inducible interleukin-10 gene transfer mediated by an adeno-associated virus: application to experimental arthritis. Hum Gene Ther 13:1179–1188PubMedCrossRef
12.
go back to reference Joosten LA, Helsen MM, Saxne T, van De Loo FA, Heinegard D, van Den Berg WB (1999) IL-1 Alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol 163:5049–5055PubMed Joosten LA, Helsen MM, Saxne T, van De Loo FA, Heinegard D, van Den Berg WB (1999) IL-1 Alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol 163:5049–5055PubMed
13.
go back to reference Tian X, Wang G, Xu Y, Wang P, Chen S, Yang H, Gao F, Xu A, Cao F, Jin X, Manyande A, Tian Y (2009) An improved tet-on system for gene expression in neurons delivered by a single lentiviral vector. Hum Gene Ther 20:113–123PubMedCrossRef Tian X, Wang G, Xu Y, Wang P, Chen S, Yang H, Gao F, Xu A, Cao F, Jin X, Manyande A, Tian Y (2009) An improved tet-on system for gene expression in neurons delivered by a single lentiviral vector. Hum Gene Ther 20:113–123PubMedCrossRef
14.
go back to reference Liu Z, Xu X, Hsu HC, Tousson A, Yang PA, Wu Q, Liu C, Yu S, Zhang HG, Mountz JD (2003) CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis. J Clin Invest 112:1332–1341PubMedCentralPubMedCrossRef Liu Z, Xu X, Hsu HC, Tousson A, Yang PA, Wu Q, Liu C, Yu S, Zhang HG, Mountz JD (2003) CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis. J Clin Invest 112:1332–1341PubMedCentralPubMedCrossRef
15.
go back to reference Agha-Mohammadi S, O’Malley M, Etemad A, Wang Z, Xiao X, Lotze MT (2004) Second-generation tetracycline-regulatable promoter: repositioned tet operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakiness. J Gene Med 6:817–828PubMedCrossRef Agha-Mohammadi S, O’Malley M, Etemad A, Wang Z, Xiao X, Lotze MT (2004) Second-generation tetracycline-regulatable promoter: repositioned tet operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakiness. J Gene Med 6:817–828PubMedCrossRef
16.
go back to reference Rang A, Will H (2000) The tetracycline-responsive promoter contains functional interferon-inducible response elements. Nucleic Acids Res 28:1120–1125PubMedCentralPubMedCrossRef Rang A, Will H (2000) The tetracycline-responsive promoter contains functional interferon-inducible response elements. Nucleic Acids Res 28:1120–1125PubMedCentralPubMedCrossRef
17.
go back to reference Villemure JF, Savard N, Belmaaza A (2001) Promoter suppression in cultured mammalian cells can be blocked by the chicken beta-globin chromatin insulator 5′HS4 and matrix/scaffold attachment regions. J Mol Biol 312:963–974PubMedCrossRef Villemure JF, Savard N, Belmaaza A (2001) Promoter suppression in cultured mammalian cells can be blocked by the chicken beta-globin chromatin insulator 5′HS4 and matrix/scaffold attachment regions. J Mol Biol 312:963–974PubMedCrossRef
18.
go back to reference Zhao H, Dean A (2005) Organizing the genome: enhancers and insulators. Biochem Cell Biol 83:516–524PubMedCrossRef Zhao H, Dean A (2005) Organizing the genome: enhancers and insulators. Biochem Cell Biol 83:516–524PubMedCrossRef
19.
go back to reference Vingsbo C, Sahlstrand P, Brun JG, Jonsson R, Saxne T, Holmdahl R (1996) Pristane-induced arthritis in rats: a new model for rheumatoid arthritis with a chronic disease course influenced by both major histocompatibility complex and non-major histocompatibility complex genes. Am J Pathol 149:1675–1683PubMed Vingsbo C, Sahlstrand P, Brun JG, Jonsson R, Saxne T, Holmdahl R (1996) Pristane-induced arthritis in rats: a new model for rheumatoid arthritis with a chronic disease course influenced by both major histocompatibility complex and non-major histocompatibility complex genes. Am J Pathol 149:1675–1683PubMed
20.
go back to reference Holmdahl R, Lorentzen JC, Lu S, Olofsson P, Wester L, Holmberg J, Pettersson U (2001) Arthritis induced in rats with nonimmunogenic adjuvants as models for rheumatoid arthritis. Immunol Rev 184:184–202PubMedCrossRef Holmdahl R, Lorentzen JC, Lu S, Olofsson P, Wester L, Holmberg J, Pettersson U (2001) Arthritis induced in rats with nonimmunogenic adjuvants as models for rheumatoid arthritis. Immunol Rev 184:184–202PubMedCrossRef
21.
go back to reference Perlman H, Pagliari LJ, Georganas C, Mano T, Walsh K, Pope RM (1999) Flice-inhibitory protein expression during macrophage differentiation confers resistance to FAS-mediated apoptosis. J Exp Med 190:1679–1688PubMedCentralPubMedCrossRef Perlman H, Pagliari LJ, Georganas C, Mano T, Walsh K, Pope RM (1999) Flice-inhibitory protein expression during macrophage differentiation confers resistance to FAS-mediated apoptosis. J Exp Med 190:1679–1688PubMedCentralPubMedCrossRef
Metadata
Title
Anti-arthritic effects of FasL gene transferred intra-articularly by an inducible lentiviral vector containing improved tet-on system
Authors
Qingyu Shi
Xuebi Tian
Yinlin Zhao
Huiyu Luo
Yuke Tian
Ailin Luo
Publication date
01-01-2014
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 1/2014
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-011-2002-z

Other articles of this Issue 1/2014

Rheumatology International 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.